Thrombosis　initiated　by　abnormal　platelet　aggregation　is　a　pivotal　pathological　event　that　precedes　most　cases　of　cardiovascular　diseases　(CVD).　Recently,　growing　evidence　indicates　that　platelet　could　be　a　potential　target　for　CVD　prevention.　However,　as　the　conventional　antithrombotic　management　strategy,　applications　of　current　antiplatelet　agents　are　somewhat　limited　by　their　various　side　effects,　such　as　bleeding　risk　and　drug　resistance.　Hence,　efforts　have　been　made　to　search　for　agents　as　complementary　therapies.　Ginsenoside,　the　principal　active　component　extracted　from　Panax　ginseng,　has　gained　much　attention　for　its　regulations　on　multiple　crucial　events　of　platelet　aggregation.　From　structural　characteristics　to　clinical　applications,　this　review　anatomized　the　intrinsic　structure-function　relationship　of　antiplatelet　potency　of　ginsenosides,　and　the　involved　signal　pathways　were　specifically　summarized.　Additionally,　the　emphasis　was　placed　on　clinical　studies　that　investigate　the　antithrombotic　efficacy　of　ginsenosides　in　the　treatment　of　CVD.　Further,　a　broad　overview　of　approaches　for　improving　the　bioavailability　of　ginsenosides　was　concluded.　Limitations　and　prospects　of　current　studies　were　also　discussed.　This　study　may　provide　some　new　insights　into　the　systematic　understanding　of　ginsenosides　in　CVD　treatment　and　lay　a　foundation　for　future　research.